Atrys Health S.A.
ISIN: ES0105148003 | Ticker: ATRY | LEI: 959800HHEE9W4TZA8627
Country: Spain
Atrys Health (BME: ATRY), founded in 2015, is a Spanish multinational that provides precision medical prediction, prevention, diagnosis and treatment services. Pioneer in the fields of telemedicine and state-of-the-art radiation therapy.
Year founded2007
Served areaWorldwide
Headcount283,200
HeadquartersCalle principe de Vergara, 132, 28002 MADRID – Spain
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | 88,691,000.00 | 180,971,000.00 | 565,632,000.00 | 705,281,000.00 |
| Noncurrent Assets | 70,663,000.00 | 143,707,000.00 | 462,526,000.00 | 602,176,000.00 |
| Property Plant And Equipment | 5,738,000.00 | 9,843,000.00 | 29,555,000.00 | 29,139,000.00 |
| Deferred Tax Assets | 5,635,000.00 | 5,805,000.00 | 9,279,000.00 | 8,874,000.00 |
| Current Assets | 18,028,000.00 | 37,264,000.00 | 103,106,000.00 | 103,105,000.00 |
| Trade And Other Current Receivables | 8,289,000.00 | 17,012,000.00 | 54,551,000.00 | 56,690,000.00 |
| Current Prepaid Expenses | 17,000.00 | 24,000.00 | 574,000.00 | 874,000.00 |
| Cash and cash equivalents | 17,476,000.00 | 35,126,000.00 | 35,126,000.00 | 34,295,000.00 |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners | 0.00 | 0.00 | 3,404,000.00 | 3,401,000.00 |
| Equity And Liabilities | 88,691,000.00 | 180,971,000.00 | 565,632,000.00 | 705,281,000.00 |
| Equity | 39,539,000.00 | 71,380,000.00 | 273,979,000.00 | 337,573,000.00 |
| Issued Capital | 256,000.00 | 347,000.00 | 614,000.00 | 760,000.00 |
| Share Premium | 38,426,000.00 | 78,079,000.00 | 315,501,000.00 | 420,053,000.00 |
| Treasury Shares | 148,000.00 | 54,000.00 | 475,000.00 | 750,000.00 |
| Noncontrolling Interests | 0.00 | 0.00 | -51,000.00 | -57,000.00 |
| Noncurrent Liabilities | 39,334,000.00 | 88,181,000.00 | 220,151,000.00 | 267,145,000.00 |
| Noncurrent Provisions | 1,966,000.00 | 15,115,000.00 | 4,256,000.00 | 3,819,000.00 |
| Noncurrent Government Grants | 5,829,000.00 | 5,714,000.00 | 5,752,000.00 | 6,745,000.00 |
| Deferred Tax Liabilities | 1,223,000.00 | 7,390,000.00 | 30,706,000.00 | 44,937,000.00 |
| Other Noncurrent Financial Liabilities | 23,591,000.00 | 47,813,000.00 | 42,331,000.00 | 38,140,000.00 |
| Noncurrent Portion Of Noncurrent Loans Received | 5,411,000.00 | 10,077,000.00 | 104,475,000.00 | 140,501,000.00 |
| Current Liabilities | 9,818,000.00 | 21,410,000.00 | 71,502,000.00 | 100,563,000.00 |
| Current Provisions | 1,049,000.00 | 875,000.00 | 12,852,000.00 | 18,074,000.00 |
| Trade And Other Current Payables | 1,910,000.00 | 5,462,000.00 | 16,041,000.00 | 24,912,000.00 |
| Current Government Grants | 268,000.00 | 310,000.00 | 294,000.00 | 294,000.00 |
| Other Current Financial Liabilities | 2,753,000.00 | 8,838,000.00 | 7,229,000.00 | 26,517,000.00 |
| Current Loans Received And Current Portion Of Noncurrent Loans Received | 2,167,000.00 | 3,150,000.00 | 12,166,000.00 | 14,363,000.00 |
| Line item in (eur) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 31,396,000.00 | 121,014,000.00 | 186,994,000.00 |
| Other Work Performed By Entity And Capitalised | 2,412,000.00 | 2,838,000.00 | 4,838,000.00 |
| Raw Materials And Consumables Used | 9,558,000.00 | 22,959,000.00 | 37,319,000.00 |
| Employee Benefits Expense | 11,033,000.00 | 70,472,000.00 | 91,730,000.00 |
| Depreciation And Amortisation Expense | 5,973,000.00 | 20,788,000.00 | 30,345,000.00 |
| Profit Loss From Operating Activities | -230,000.00 | -15,014,000.00 | -11,117,000.00 |
| Finance Income | 210,000.00 | 1,848,000.00 | 2,906,000.00 |
| Finance Costs | 4,419,000.00 | 9,969,000.00 | 15,218,000.00 |
| Profit Loss Before Tax | -5,381,000.00 | -24,882,000.00 | -24,693,000.00 |
| Income Tax Expense Continuing Operations | 167,000.00 | -1,685,000.00 | -1,225,000.00 |
| Profit Loss From Continuing Operations | -5,548,000.00 | -23,197,000.00 | -23,468,000.00 |
| Profit Loss From Discontinued Operations | 0.00 | -46,000.00 | -49,000.00 |
| Profit (loss) | -5,548,000.00 | -23,243,000.00 | -23,517,000.00 |
| Profit Loss Attributable To Owners Of Parent | -5,548,000.00 | -23,255,000.00 | -23,259,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 12.00 | -258.00 |
| Line item in (eur) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -5,548,000.00 | -23,243,000.00 | -23,517,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 10,313,000.00 | 39,481,000.00 | 37,791,000.00 |
| Adjustments For Finance Costs | N/A | 4,419,000.00 | 9,969,000.00 | 15,218,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | -43,000.00 | 121,000.00 | 304,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 5,973,000.00 | 20,788,000.00 | 30,345,000.00 |
| Adjustments For Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss | N/A | 141,000.00 | 1,075,000.00 | 3,842,000.00 |
| Adjustments For Provisions | N/A | 149,000.00 | -1,065,000.00 | -2,068,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | N/A | 0.00 | 829,000.00 |
| Other Adjustments To Reconcile Profit Loss | N/A | 152,000.00 | 10,457,000.00 | -10,103,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 10,313,000.00 | 39,481,000.00 | 37,791,000.00 |
| Interest Paid Classified As Operating Activities | N/A | 2,494,000.00 | 9,969,000.00 | 15,218,000.00 |
| Interest Received Classified As Operating Activities | N/A | 210,000.00 | 1,133,000.00 | 2,906,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 385,000.00 | 1,085,000.00 | 2,479,000.00 |
| Other Inflows Outflows Of Cash Classified As Operating Activities | N/A | -2,669,000.00 | -9,921,000.00 | -14,791,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -1,395,000.00 | 4,694,000.00 | -15,434,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | 0.00 | 18,185,000.00 | 0.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 3,195,000.00 | -4,223,000.00 | -6,769,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 2,095,000.00 | -4,344,000.00 | -8,392,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -52,083,000.00 | -2,449,000.00 | -80,586,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 5,143,000.00 | 118,020,000.00 | 49,861,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 2,430,000.00 | 92,668,000.00 | 29,497,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 62,625,000.00 | 14,081,000.00 | 94,773,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | 1,324,000.00 | 416,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 9,147,000.00 | 17,650,000.00 | -831,000.00 |
| Cash and cash equivalents | 17,476,000.00 | 35,126,000.00 | 35,126,000.00 | 34,295,000.00 |
Please note that some sums might not add up.
ES0105148003
LEI959800HHEE9W4TZA8627
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.